A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have high lipoprotein(a) level, at least 175 nmol/L, and either:
Be at least 18 years old and have had a cardiac event (like a heart attack or cardiac bypass surgery), a stroke, or peripheral arterial event (like a stent in an artery in the leg or an amputation)
Or
Be at least 55 years old and have risk factors for a cardiac event, like narrowing of the coronary or carotid arteries; a condition called familial hypercholesterolemia; or a group of other risk factors for cardiovascular disease
Participants Must Not:
Have had major surgery, cardiac event, or stroke within 90 days of day 1
Have very high blood pressure
Have kidney failure that requires dialysis
Have chronic liver problems
Have cancer
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo